New combo device aims to keep patients breathing safely during lung scope

NCT ID NCT07063290

Completed Symptom relief Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new device called the COMBO Endoscopy Oropharyngeal Airway in 104 adults undergoing a sedated lung procedure (fiberoptic bronchoscopy). The device combines oxygen delivery, airway support, and breathing monitoring into one tool. The goal was to see if it could reduce episodes of low oxygen (hypoxia) compared to standard care. If successful, it could make these common procedures safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COMBO Endoscopy Oropharyngeal Airway (a device that provides oxygen, monitors breathing, and keeps the airway open)
What this could lead to: If it works, this device could reduce the risk of dangerously low oxygen levels during sedated bronchoscopy, making the procedure safer and more comfortable.
What could go wrong: This is a small, early-phase trial (104 people) testing a device, not a new drug. The device may not work better than standard care, and results may not apply to all patients or longer procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis Hypoxia respiratory tract infectious disorder trachea neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIECTASIS ENDOTRACHEAL TUMOUR PULMONARY INFECTION PULMONARY NODULE

Contacts and locations

Locations

The First Affliated Hospital, Zhejiang University School Of Medicine

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.